The gabapentin market is registering a valuation of US$ 2.11 billion in 2023 and is estimated to reach US$ 3.54 billion by 2033. The market is securing a CAGR of 5.3% during the forecast period.
The market has been growing rapidly due to several driving factors, including:
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 5.3% |
| Market Valuation (2023) | US$ 2.11 billion |
| Market Valuation (2033) | US$ 3.54 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Despite the growth drivers, several factors may restrain the market, including:
According to the FMI report, the global market size was valued at US$ 2.03 billion in 2020 with a CAGR of 4.6%. The increasing prevalence of neurological disorders, such as epilepsy and neuropathic pain, are the primary indications for gabapentin.
Regarding geographic segmentation, North America is expected to dominate the gabapentin market during the forecast period. It can be attributed to the high prevalence of neurological disorders and the presence of leading pharmaceutical companies in the region. Market trends and projections can change rapidly depending on various factors, including competition and technological advances.
Principal Consultant
Gabapentin is available in various dosage forms, including capsules, tablets, oral solutions, and extended-release formulations. However, is commonly prescribed form of gabapentin is oral capsules.
According to FMI, the capsule segment dominate the market, accounting for a significant share by 2033. It can be attributed to the ease of administration and accurate dosing provided by capsules and their widespread availability.
Tablets are also a popular dosage form for gabapentin, commonly prescribed for patients who have difficulty swallowing capsules. Oral solutions and extended-release formulations of gabapentin are relatively less common. They may be prescribed in certain cases, such as for patients with difficulty swallowing or requiring a more controlled release of the medication.
Gabapentin primarily treats epilepsy and neuropathic pain, including diabetic neuropathy, post-herpetic neuralgia, and trigeminal neuralgia. It is also used off-label for conditions such as anxiety disorders and insomnia.
In terms of type, the gabapentin market is segmented into branded and generic products. The generic segment dominates the market by capturing a significant share by 2033. The availability of several generic drug versions at lower prices leads to increased treatment options.
The market in the United States is significant, with the drug being one of the most widely prescribed medications in the country. Gabapentin is primarily used to treat epilepsy and neuropathic pain. However, it is also prescribed off-label for a range of other conditions, including anxiety disorders and insomnia.
According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020. The report also notes that gabapentin was the country's second-leading prescribed medication for neuropathic pain after pregabalin.
The market in the United States is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. However, branded versions of gabapentin, such as Neurontin, continue to hold a significant market share, particularly for certain indications.
The gabapentin market in the United States is expected to grow in the coming years. Due to the aging population, increasing prevalence of neuropathic pain conditions, and a growing awareness of the drug's efficacy in treating.
The gabapentin market in the United Kingdom is also significant, with the drug being widely prescribed for treating epilepsy and neuropathic pain. Gabapentin is available in various formulations, including capsules, tablets, and oral solutions.
According to a report by the United Kingdom National Health Service, gabapentin was the fourth commonly prescribed medication in 2020. The report also notes that gabapentin was the country's highly prescribed medication for neuropathic pain.
The market in the United Kingdom is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. The branded versions of gabapentin, such as Neurontin, also hold a significant market share.
The United Kingdom has faced increased scrutiny due to concerns about the drug's potential for abuse and addiction. In 2019, gabapentin and pregabalin were reclassified as Class C controlled substances. They are subject to more stringent prescribing and dispensing requirements to reduce the risk of diversion and misuse.
Japan gabapentin market has been growing steadily in recent years, driven by the increasing prevalence of conditions such as epilepsy and neuropathic pain. Additionally, the availability of generic versions of the drug has made it more affordable and accessible for patients.
Regarding market competition, several domestic and international companies offer generic versions of gabapentin in Japan. These companies include Towa Pharmaceutical Co. Ltd., Nippon Chemiphar Co. Ltd., and Teva Pharmaceutical Industries Ltd. The branded gabapentin, Neurontin, is also available in Japan through Pfizer Japan Inc.
In recent years, the market in Japan has faced challenges related to concerns about the drug's potential for abuse and addiction. It has led to stricter regulations for the prescribing and dispensing of gabapentin and other similar drugs, potentially impacting the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The gabapentin market is highly competitive, with many pharmaceutical companies manufacturing and marketing the drug. The market is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. However, branded versions of gabapentin, such as Neurontin, also hold a significant market share.
The key players in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., and Mylan N.V. These companies have a strong presence in the market and offer a range of gabapentin formulations and dosages.
These established players and several emerging pharmaceutical companies are also entering the market, driven by the growing demand for the drug. The companies focus on developing novel formulations and delivery methods for gabapentin, improving patient outcomes, and expanding the market.
Other Essential Players in the Market are:
Recent Developments in the Market are:
Several key companies, including Pfizer, Teva Pharmaceutical Industries, Mylan, and Hikma Pharmaceuticals are dominating the global market. Here are some recent developments from these companies in the global market:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Regions Covered | North America, Latin America, The Middle East and Africa, Europe, and Asia Pacific |
| Key Segments Covered |
|
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The Gabapentin market is valued at US$ 2.11 billion in 2023.
Some of the key players in the Gabapentin market include Pfizer, Sun Pharmaceutical Industries, Mylan, and Teva Pharmaceutical Industries.
Capsules are likely to remain preferred through 2033.
Players opt for product launches and partnerships.
India, Japan, and China dominate the Asian market.
1. Executive Summary | Gabapentin Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
5.3.1. Tablet
5.3.2. Capsule
5.3.3. Oral Solution
5.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Generic
6.3.2. Branded
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
7.3.1. Epilepsy
7.3.2. Neuropathic Pain
7.3.3. Restless Legs Syndrome
7.3.4. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Dosage Form
10.2.3. By Type
10.2.4. By Application
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Dosage Form
10.3.3. By Type
10.3.4. By Application
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Dosage Form
11.2.3. By Type
11.2.4. By Application
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Dosage Form
11.3.3. By Type
11.3.4. By Application
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Dosage Form
12.2.3. By Type
12.2.4. By Application
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Dosage Form
12.3.3. By Type
12.3.4. By Application
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Dosage Form
13.2.3. By Type
13.2.4. By Application
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Dosage Form
13.3.3. By Type
13.3.4. By Application
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Dosage Form
14.2.3. By Type
14.2.4. By Application
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Dosage Form
14.3.3. By Type
14.3.4. By Application
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Dosage Form
15.2.3. By Type
15.2.4. By Application
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Dosage Form
15.3.3. By Type
15.3.4. By Application
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Dosage Form
16.2.3. By Type
16.2.4. By Application
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Dosage Form
16.3.3. By Type
16.3.4. By Application
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Dosage Form
17.1.2.2. By Type
17.1.2.3. By Application
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Dosage Form
17.2.2.2. By Type
17.2.2.3. By Application
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Dosage Form
17.3.2.2. By Type
17.3.2.3. By Application
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Dosage Form
17.4.2.2. By Type
17.4.2.3. By Application
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Dosage Form
17.5.2.2. By Type
17.5.2.3. By Application
17.5.2.4. By Distribution Channel
17.6. United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Dosage Form
17.6.2.2. By Type
17.6.2.3. By Application
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Dosage Form
17.7.2.2. By Type
17.7.2.3. By Application
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Dosage Form
17.8.2.2. By Type
17.8.2.3. By Application
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Dosage Form
17.9.2.2. By Type
17.9.2.3. By Application
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Dosage Form
17.10.2.2. By Type
17.10.2.3. By Application
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Dosage Form
17.11.2.2. By Type
17.11.2.3. By Application
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Dosage Form
17.12.2.2. By Type
17.12.2.3. By Application
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Dosage Form
17.13.2.2. By Type
17.13.2.3. By Application
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Dosage Form
17.14.2.2. By Type
17.14.2.3. By Application
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Dosage Form
17.15.2.2. By Type
17.15.2.3. By Application
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Dosage Form
17.16.2.2. By Type
17.16.2.3. By Application
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Dosage Form
17.17.2.2. By Type
17.17.2.3. By Application
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Dosage Form
17.18.2.2. By Type
17.18.2.3. By Application
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Dosage Form
17.19.2.2. By Type
17.19.2.3. By Application
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Dosage Form
17.20.2.2. By Type
17.20.2.3. By Application
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Dosage Form
17.21.2.2. By Type
17.21.2.3. By Application
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Dosage Form
18.3.3. By Type
18.3.4. By Application
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Zydus Pharmaceuticals, Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Glenmark Pharmaceuticals Limited
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Sun Pharmaceutical Industries Ltd.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Ascend Laboratories, LLC
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Apotex Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Teva Pharmaceutical Industries Ltd.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Aurobindo Pharma
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Amneal Pharmaceuticals LLC.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Cipla USA, Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. BP Pharmaceuticals Laboratories Company
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Assertio Holdings, Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Arbor Pharmaceuticals, Inc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Pfizer Inc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Gabapentin Market
